AMRX Q4 2019 Earnings — Amneal Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMRXAmneal Pharmaceuticals, Inc.

$4B

Q4 2019 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$397M-20.1% YoY

Gross Profit

$110M27.7% margin

Operating Income

-$23M-5.8% margin

Net Income

-$32M-8.1% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

+5.0%

Cash Flow

Operating Cash Flow

-$51M

Free Cash Flow

-$56M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$3.7B

Total Liabilities

$3.3B

Stockholders' Equity

$232M

Cash & Equivalents

$151M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$397M	$498M	-20.1%
Gross Profit	$110M	$193M	-43.0%
Operating Income	-$23M	$23M	-199.4%
Net Income	-$32M	-$9M	-266.4%

Revenue Segments

Generics Segment

$300M76%

Amneal Specialty Pharma Segment

$97M24%